{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"43"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"301"},{"groupId":"OG001","value":"300"}],"units":"Participants"}],"description":"Recurrence-Free Survival is the period from study entry until disease recurrence, death, or date of last contact","groups":[{"description":"Patients undergo conventional or intensity-modulated pelvic radiation therapy once daily, 5 days a week, for 5-6 weeks (total of 25-28 fractions) in the absence of disease progression or unacceptable toxicity. Patients with stage II disease or stage I disease with a confirmed diagnosis of clear cell and/or papillary serous histology may also undergo 1 or 2 intravaginal (i.e., vaginal cuff) brachytherapy boost treatments.\n\n3-Dimensional Conformal Radiation Therapy: Undergo pelvic radiation therapy\n\nIntensity-Modulated Radiation Therapy: Undergo pelvic radiation therapy\n\nInternal Radiation Therapy: Undergo vaginal cuff brachytherapy\n\nLaboratory Biomarker Analysis: Correlative studies\n\nQuality-of-Life Assessment: Ancillary studies\n\nQuestionnaire Administration: Ancillary studies","id":"OG000","title":"Arm I (Pelvic Radiation Therapy)"},{"description":"Patients undergo vaginal cuff brachytherapy comprising 3-5 high-dose rate brachytherapy treatments over approximately 2 weeks or 1 or 2 low-dose rate brachytherapy treatments over 1-2 days. Beginning within 3 weeks after initiating brachytherapy, patients receive paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 1. Chemotherapy repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.\n\nCarboplatin: Given IV\n\nInternal Radiation Therapy: Undergo vaginal cuff brachytherapy\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPaclitaxel: Given IV\n\nQuality-of-Life Assessment: Ancillary studies\n\nQuestionnaire Administration: Ancillary studies","id":"OG001","title":"Arm II (Brachytherapy, Paclitaxel, Carboplatin)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All enrolled patients","reportingStatus":"POSTED","timeFrame":"Within 4 weeks after completing or discontinuing study therapy, then every 6 months for 2 years, then annually for 3 years, then as clinically indicated, assessed up to 10 years","title":"Number of Participants With Recurrence or Death Events at Primary Analysis","type":"PRIMARY","unitOfMeasure":"Participants"}